The Team
Management
Guy Yachin, BSc., MBA
Co-Founder & CEO
Dr. Ethan Ludmir, M.D.
CMO (Interim)
Assistant Professor, Dept. of Gastrointestinal Radiation Oncology and Department of Biostatistics, MD Anderson Cancer Center, Houston, TX. Dr. Ludmir has considerable expertise in trial design in radiation oncology and in biostatistical methodology.
Dr. Michael Shtein, Ph.D, MBA
Co-Founder & CSO
Entrepreneur with over 20 years of Managerial and R&D Experience, Dr. Shtein is an expert in commercializing an academia concepts to products and is a cofounder of several biomed companies.
Dr. Jessica Molkentine
Pre-clinical Director
Jessica serves as the company’s Director of Clinical Development. In addition to my role with Xerient, I’m currently an Associate Scientist at UT MD Anderson Cancer Center with 19 years of experience in preclinical and translational cancer research and a background in radiation oncology.
Robbin Frnka
Clinical Director
Experienced clinical research and operations leader with more than 20 years in oncology and immunology drug development. As Co-Founder and Head of Scientific Affairs at AccelSoBio, she has led clinical programs across biotech, CRO, and academic settings, bringing deep expertise in trial strategy and execution. She holds a B.S. in Zoological Sciences from Oklahoma State University, with graduate studies in genetics and pharmacology.
Jeanne Jones
Clinical Project Manager
Clinical research leader with over 30 years of experience across oncology, neurology, and diagnostics. She has held senior roles at Mary Crowley Cancer Research, Genzyme, US Oncology, and Proxima CRO, bringing deep expertise in early-phase trials, operational strategy, and patient-centered research execution. Jeanne has supported trials across all phases and therapeutic modalities, partnering with sponsors, sites, and investigators to advance innovative treatments. She holds an M.S.N. from the University of Nebraska and a B.S.N. from the University of Iowa.
Danit Licht
Formulation Director
Expert in Pharmaceutical R&D for more than 30 years, Responsible the development of known products. Served as Associate Director in the Innovative Pharma R&D of TEVA, Taro Pharmaceutical and various pharmaceutical firms.
Danit Holds B.F.E&B (Bachelor of Food Engineering and Biotechnology) from the Technion Institute, Haifa, and M.Sc in Pharmaceutical Chemistry at the Bar-Ilan University and B.Sc in Chemistry (especially in Organic Chemistry) at the Tel-Aviv University, Israel. Danit Issued dozens of patents worldwide and published articles.
Board of directors
Guy Hoffman
Director
30-year investment and fund-manager veteran with direct experience in capital formation. Managing Member of NewTech Investment Holdings, an advanced materials and Bio/MedTech investment vehicle. Former co-founder, partner and investment committee member of Chambers Energy Capital, an energy investment fund for more than a decade. Board member of Nanorobotics, Ltd., Cobionix Corporation and Xerient Pharma Ltd. among others.
Mr. Eyal Lifschitz
Director
Eyal Lifschitz is a business founder and entrepreneur with years of experience establishing and managing medical technology companies and their business development efforts. Eyal was involved as a founder and a manger in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. and as a director of Given Imaging (NASDAQ: GIVN).
He holds an LLB from the Academic Center for Law and Science.
Mr. Doron Eldar
Director
Result-focused entrepreneur with more than a decade of experience in senior leadership roles and is currently a Melbourne-based partner at venture capital fund SIBF.
Mr Eldar has extensive experience scaling innovative tech companies globally, formulating effective go-to-market strategies and driving market awareness for private and public tech companies.
Doron is also a venture partner at Oxen9 and a Director at Dotz Nano (ASX:DTZ), Electric Global, Livia and others.
To be announced
Proposed Chairman of the Board
Scientific team and Advisors
Dr. Zan Fleming, M.D.
Regulatory Advisor
Prof. Daniel D. Von Hoff M.D.
Chief Medical Advisor
Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts
Mr. Ofer Doron
Pre-clinical Advisor
Mr. Doron was the Manging Director of Lahav Research Institute (the largest large animals CRO in Israel) for 13 years. He was involved in the development of many medical devices and Pharmaceutical products. Mr. Doron serves today as a cosultant to various companies, he joined Xerient Pharma in 2020.
Prof. Cullen Taniguchi, M.D,
1976 - 2023
Co-Founder
Board-certified radiation oncologist he was an Assistant Professor in Radiation Oncology at MD Anderson Cancer Center, specializing in treating gastrointestinal malignancies, with a clinical focus on unresectable pancreatic cancer.
